Hyponatremia
Conditions
Interventions
1.Desmopressin-treated group
Desmopressin: 2 micrograms diluted in 20 mL or 50 mL of saline and administered intravenously slowly over 10 to 20 minutes, repeated every 8 hours, 3 times a day, until se
Sponsors
Iwata Mitsunaga
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients aged 20 years or older at the time of obtaining consent 2.Patients diagnosed with hyponatremia based on the diagnostic criteria of a sodium level of 120 mEq/L or less in blood tests 3.Patients who have given their free written consent to participate in this study after receiving sufficient explanation and understanding
Exclusion criteria
Exclusion criteria: 1. Patients on regular DDAVP medication 2. Patients taking oral tolvaptan 3. Patients with hyponatremia diagnosed as isotonic or hypertonic 4. Patients diagnosed with hypotonic hyponatremia who are diagnosed with heart failure according to 2021ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 5. Patients admitted towards other than ICU or ICU equivalent wards, and patients already hospitalized for other diseases 6. Other patients who are judged inappropriate by the principal investigator or sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum delta serum sodium level at 24 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| Maximum delta serum sodium level at 48 hours Safe sodium correction rate at 24 hours Safe sodium correction rate at 48 hours Safe sodium correction rate at each 24-hour period from start to 48 hours The total volume of fluids administered ICU length of stay Length of hospital stay Incidence of adverse effects | — |
Contacts
Public ContactTeruhiko Terasawa
Fujita Health University Hospital
Outcome results
None listed